Signed documents are available upon request.
Conflict of Interest – Confidentiality (POL001)
Define areas of conflict of interest and identifies when disclosure should be provided to eventually place limitations on investigators’ participation in EORTC activities.
Protection of Human Subjects Participating in Clinical and Translational Research (POL002)
It provides guidance on how to ensure the protection of the rights, safety and well-being of trial subjects pertaining to all EORTC activities within the European framework. This policy also ensures homogeneous conduct of studies involving biological material from patients who have participated in EORTC clinical trials.
Research Misconduct (POL003)
It describes the review of research misconduct allegation and the subsequent investigation and outcome.
Independent Data Monitoring Committees for EORTC studies (POL004)
It describes the use of Independent Data Monitoring Committees in EORTC clinical trials.
Intergroup Studies (POL005)
It outlines the EORTC policy on intergroup studies in order to facilitate this type of collaboration.
Criteria and guidelines for giving the EORTC label to scientific meetings (POL006)
Its describes what is an EORTC labeled meeting and conditions to use the EORTC logo.
Scientific Audit Committee (POL007)
It describes the responsibilities of the Scientific Audit Committee (SAC) and the process of EORTC group review.
Data Sharing (POL008)
It defines the terms and conditions under which electronic records of individual data from all or from subsets of the patients from EORTC studies may be shared with other organizations or individual researchers for the purpose of scientific research projects or may be posted on data repositories.
Disclosure of Results and Publication Policy (POL009)
Policy regarding study publication (incl. timing; authorship and acknowledgement rules; review process; conditions of publication of safety, TR of ancillary studies rel to the protocol and their authorization process; research results from the use of biological material from clinical studies).
New Drug Advisory Committee (NDAC) (POL013)
Describes the missions and tasks of this committee which supports and gives recommendations to the clinical research groups in new drug development within the EORTC network. It describes also the interaction between NDAC and the EORTC Headquarters Early Project Optimization Department.
Translational Research Advisory Committee (TRAC) (POL014)
It outlines the missions and tasks of the Translational Research Advisory Committee (TRAC) and the interaction with the EORTC Headquarters (HQ).
Protocol Development Process, Selection and Approval Procedures for EORTC Studies (POL016)
It describes the protocol development process and the selection and approval procedures for EORTC studies, focuses on the role of the different EORTC committees in the study selection and development, on the criteria used at different milestones, and on the process for submitting study proposals to EORTC and developing them into full protocols.
EORTC principles for investigational sites activation (POL018)
Describes the principles for investigational site participation to EORTC studies.
Developing EORTC Guidelines, Expert Opinions, and the use of EORTC Results in Promotional Material on Cancer Care (POL019)
EORTC as a clinical research organisation needs to create a structure for the development and approval of documents that are published as recommendations. These documents are encouraged, as they will increase the EORTC’s visibility and quality of cancer care and should be published in a peer reviewed journal. The forms of these recommendations need to comply with international references for level of evidence and be in compliance with EORTC missions. This policy does not apply to individual studies but to the recommendations dedicated to a specific clinical or methodological situation.
Human Biological Material Collection, Storage and Use (POL020)
It defines the position of the EORTC concerning the management of HBM collected from participants enrolled in EORTC studies and projects with regards to collection storage and use. It outlines the minimal principles for both EORTC and non-EORTC parties.
Protection of Personal data (POL021)
EORTC legitimate mission is to coordinate and conduct throughout its network and in collaboration with third parties,
international prospective and retrospective translational and clinical research to improve the standard of cancer
treatment for patients. Aside this primary mission, EORTC also develops and improves research methodologies and
tools and organizes educational events and courses. Last, but not the least, EORTC also raises funds to support its
This policy describes how EORTC ensure protection of personal data it processes as a data controller and as a data